FDA and FTC cite Ar-Rahman Pharm for Diabetes Support sold with unapproved diabetes-treatment claims.
What happened
FDA reviewed the company's website and its Instagram and Facebook pages in August 2021 and found it takes orders for Diabetes Support, a dietary supplement. The sites claimed the product helps balance blood sugar, supports the pancreas, and helps manage diabetes. FDA says those claims make it an unapproved new drug and misbranded, and FTC also reviewed the sites and issued a cease and desist demand over unsubstantiated disease claims.
What FDA found
Website and social media claims that Diabetes Support helps balance blood sugar and supports the pancreas show the product is intended to treat or prevent diabetes, which makes it a drug under the law.
section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)]The product is not generally recognized as safe and effective for those uses, so it is an unapproved 'new drug' sold without FDA approval.
sections 201(p), 301(d), and 505(a) of the FD&C Act [21 U.S.C. 321(p), 331(d), 355(a)]The product lacks adequate directions for use because diabetes cannot be safely self-diagnosed or treated by a layperson without a licensed practitioner.
section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling the misbranded product in interstate commerce violates the law.
section 301(a) of the FD&C Act [21 U.S.C. 331(a)]FTC says the company advertised that a product can prevent, treat, or cure diabetes without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. ยง 41 et seq.
What FDA wants
FDA asks the company to notify FDA in writing within 15 working days of the specific steps taken to address the violations, including steps to prevent recurrence, and to include related documentation. If corrective actions cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- companies selling dietary supplements with disease-treatment claims
- brands and contract manufacturers of diabetes-related supplements
- marketing and compliance teams that manage supplement websites and social media
This is a summary. Read the original letter on fda.gov.